ARTICLE | Clinical News
Necuparanib regulatory update
January 5, 2015 8:00 AM UTC
FDA granted Fast Track designation to necuparanib from Momenta for first-line treatment of metastatic pancreatic cancer in combination with Abraxane nab-paclitaxel and gemcitabine. The heparin sulfa...